Literature DB >> 15765097

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.

Mario F Fraga1, Esteban Ballestar, Ana Villar-Garea, Manuel Boix-Chornet, Jesus Espada, Gunnar Schotta, Tiziana Bonaldi, Claire Haydon, Santiago Ropero, Kevin Petrie, N Gopalakrishna Iyer, Alberto Pérez-Rosado, Enrique Calvo, Juan A Lopez, Amparo Cano, Maria J Calasanz, Dolors Colomer, Miguel Angel Piris, Natalie Ahn, Axel Imhof, Carlos Caldas, Thomas Jenuwein, Manel Esteller.   

Abstract

CpG island hypermethylation and global genomic hypomethylation are common epigenetic features of cancer cells. Less attention has been focused on histone modifications in cancer cells. We characterized post-translational modifications to histone H4 in a comprehensive panel of normal tissues, cancer cell lines and primary tumors. Using immunodetection, high-performance capillary electrophoresis and mass spectrometry, we found that cancer cells had a loss of monoacetylated and trimethylated forms of histone H4. These changes appeared early and accumulated during the tumorigenic process, as we showed in a mouse model of multistage skin carcinogenesis. The losses occurred predominantly at the acetylated Lys16 and trimethylated Lys20 residues of histone H4 and were associated with the hypomethylation of DNA repetitive sequences, a well-known characteristic of cancer cells. Our data suggest that the global loss of monoacetylation and trimethylation of histone H4 is a common hallmark of human tumor cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765097     DOI: 10.1038/ng1531

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  624 in total

Review 1.  The role of epigenetic regulation in stem cell and cancer biology.

Authors:  Lilian E van Vlerken; Elaine M Hurt; Robert E Hollingsworth
Journal:  J Mol Med (Berl)       Date:  2012-06-02       Impact factor: 4.599

Review 2.  Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Authors:  Maribel Cotto; Fernando Cabanillas; Maribel Tirado; María V García; Eileen Pacheco
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

Review 3.  Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma.

Authors:  Günter Schneider; Oliver H Krämer; Roland M Schmid; Dieter Saur
Journal:  J Gastrointest Cancer       Date:  2011-06

4.  Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.

Authors:  Eun-Taex Oh; Moon-Taek Park; Bo-Hwa Choi; Seonggu Ro; Eun-Kyung Choi; Seong-Yun Jeong; Heon Joo Park
Journal:  Invest New Drugs       Date:  2010-10-27       Impact factor: 3.850

5.  Chaperone-mediated acetylation of histones by Rtt109 identified by quantitative proteomics.

Authors:  Nebiyu Abshiru; Kevin Ippersiel; Yong Tang; Hua Yuan; Ronen Marmorstein; Alain Verreault; Pierre Thibault
Journal:  J Proteomics       Date:  2012-10-02       Impact factor: 4.044

6.  Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.

Authors:  Stefani N Thomas; Lijun Chen; Yang Liu; Naseruddin Höti; Hui Zhang
Journal:  J Proteome Res       Date:  2017-09-14       Impact factor: 4.466

Review 7.  Dietary agents as histone deacetylase inhibitors.

Authors:  Melinda C Myzak; Emily Ho; Roderick H Dashwood
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

8.  GRIP1-associated SET-domain methyltransferase in glucocorticoid receptor target gene expression.

Authors:  Yurii Chinenov; Maria A Sacta; Anna R Cruz; Inez Rogatsky
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-11       Impact factor: 11.205

Review 9.  Epigenomics and breast cancer.

Authors:  Pang-Kuo Lo; Saraswati Sukumar
Journal:  Pharmacogenomics       Date:  2008-12       Impact factor: 2.533

10.  Epigenetic Therapy in Breast Cancer.

Authors:  Maryam B Lustberg; Bhuvaneswari Ramaswamy
Journal:  Curr Breast Cancer Rep       Date:  2011-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.